2024年1月至10月，芬兰在一场持续的疫情中发现了耐大环内酯类菌株。

Miettinen Milja, Barkoff Alex-Mikael, Nyqvist Aino, Savolainen-Kopra Carita, Antikainen Jenni, Mertsola Jussi, Ivaska Lauri, He Qiushui

Finnish Reference Laboratory for Diphtheria and Pertussis, Institute of Biomedicine, University of Turku, Turku, Finland.

Department of Paediatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Turku, Finland.

Euro Surveill. 2024 Dec;29(49). doi: 10.2807/1560-7917.ES.2024.29.49.2400765.

Since April 2024, a pertussis epidemic has been ongoing in Finland with 2,215 notified cases by end October. Of them, 30.1% (n = 667) were aged 10-14 years. Of the 462 isolates characterised, one was macrolide-resistant (minimum inhibitory concentration (MIC) of erythromycin, azithromycin and clarithromycin > 256 μg/mL). The resistant isolate was serotype FIM2, vaccine antigen pertactin-deficient and harboured allele. The emergence of macrolide-resistant in Europe is worrisome and its rapid identification is important.

自2024年4月以来，芬兰一直在发生百日咳疫情，截至10月底已报告2215例病例。其中，30.1%（n = 667）为10至14岁的儿童。在462株已鉴定的分离株中，有1株对大环内酯类耐药（红霉素、阿奇霉素和克拉霉素的最低抑菌浓度（MIC）>256μg/mL）。该耐药分离株为FIM2血清型，缺乏疫苗抗原百日咳杆菌黏附素，并携带等位基因。欧洲出现大环内酯类耐药令人担忧，快速鉴定耐药菌株很重要。